日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Efficacy, safety, and exploratory biomarker analysis of envafolimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: a prospective, single-arm, phase II trial

恩伐利单抗联合卡铂和依托泊苷一线治疗广泛期小细胞肺癌的疗效、安全性及探索性生物标志物分析：一项前瞻性、单臂、II期试验

期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-025-04385-4
Zhao, Xiao; Zhang, Jing; Qiu, Lupeng; Han, Quanli; Yan, Xiang; Zhu, Yanyun; Wang, Jinliang; Zhang, Xiaoling; Jiao, Shunchang; Sun, Shengjie
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Nimotuzumab plus chemotherapy and immunotherapy as first-line/neoadjuvant therapy for advanced esophageal squamous cell carcinoma

尼妥珠单抗联合化疗和免疫疗法作为晚期食管鳞状细胞癌的一线/新辅助治疗

期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2025.1585048
Wang, Qi; Cui, Zhi; Deng, Muhong; Zhang, Guoqing; Jing, Fangfang; Ma, Yue; Pang, Fang; Han, Quanli
细胞生物学
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏

Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer

信迪利单抗联合贝伐珠单抗和CAPOX方案作为RAS突变、微卫星稳定型转移性结直肠癌患者一线治疗的疗效和安全性

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-025-13794-w
Wang, Yanrong; Jia, Ru; Si, Haiyan; Ma, Yue; Fan, Mengjiao; Zhang, Nan; Liu, Fangfang; Shi, Yue; Jia, Yushan; Zhang, Yaoyue; Han, Quanli; Wang, Zhikuan; Dai, Guanghai
RAS
肿瘤
肠癌
肿瘤免疫
发表日期：2025
文献求助 收藏

TIGD6 in gastric cancer: exploring its prognostic value and therapeutic potential through molecular and clinical investigations.

TIGD6 在胃癌中的作用：通过分子和临床研究探索其预后价值和治疗潜力。

期刊:European Journal of Medical Research
影响因子:3.4
doi:10.1186/s40001-025-03219-6
Han Quanli, Deng Muhong, Cui Zhi, Wang Qi, Li Dongbing
胃癌
肿瘤
肿瘤免疫
IGD
发表日期：2025
文献求助 收藏

Association of lung immune prognostic index with overall survival in pancreatic ductal adenocarcinoma patients treated using chemotherapy

肺免疫预后指数与接受化疗的胰腺导管腺癌患者总生存期的相关性

期刊:International Journal of Medical Sciences
影响因子:3.2
doi:10.7150/ijms.102404
Zhang, Nan; Deng, Guochao; Jia, Ru; Han, Quanli; Dai, Guanghai
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏

Gene signature developed for predicting early relapse and survival in early-stage pancreatic cancer

针对早期胰腺癌，开发了一种基因特征来预测早期复发和生存率。

期刊:BJS Open
影响因子:4.5
doi:10.1093/bjsopen/zrad031
Huang, Lei; Yuan, Xiaodong; Zhao, Liangchao; Han, Quanli; Yan, Huan; Yuan, Jing; Guan, Shasha; Xu, Xiaofeng; Dai, Guanghai; Wang, Junqing; Shi, Yan
胰腺癌
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications

中国胰腺癌患者致病性基因组改变及其治疗意义

期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.5871
Zhao, Zhiming; Li, Xiaomo; Wang, Fei; Xu, Yong; Liu, Si; Han, Quanli; Yang, Zhiying; Huang, Weiwei; Yin, Zhuzeng; Liu, Qu; Tan, Haidong; Ma, Tonghui; Si, Shuang; Huang, Jia; Yuan, Hongling; Li, Wei; Liu, Rong
胰腺癌
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Case Report and Literature Review: Diagnosis, Tailored Genetic Counseling and Cancer Prevention for a Locally Advanced dMMR/MSI-H/TMB-H Lung Cancer Patient With Concurrent Lynch Syndrome Mediated by a Rare PMS2 Splicing Variant (c.1144+1G>A)

病例报告和文献综述：由罕见的 PMS2 剪接变异 (c.1144+1G>A) 介导的局部晚期 dMMR/MSI-H/TMB-H 肺癌合并林奇综合征患者的诊断、个体化遗传咨询和癌症预防

期刊:Frontiers in Genetics
影响因子:2.8
doi:10.3389/fgene.2021.799807
Han, Quanli; Liu, Si; Cui, Zhi; Wang, Qi; Ma, Tonghui; Jiang, Liwen; Li, Xiaomo; Dai, Guanghai
肺癌
肿瘤
肿瘤免疫
多发性骨髓瘤
多发性硬化症
发表日期：2021
文献求助 收藏

Survival of patients with advanced pancreatic cancer after iodine125 seeds implantation brachytherapy: A meta-analysis

碘125粒子植入近距离放射治疗晚期胰腺癌患者的生存率：一项荟萃分析

期刊:Medicine
影响因子:1.4
doi:10.1097/MD.0000000000005719
Han, Quanli; Deng, Muhong; Lv, Yao; Dai, Guanghai
胰腺癌
肿瘤
肿瘤免疫
发表日期：2017
文献求助 收藏

Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial

晚期胰腺腺癌患者接受白蛋白结合型紫杉醇联合S-1治疗（NPSPAC）：一项单臂、单中心II期临床试验

期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.21359
Shi, Yan; Zhang, Sui; Han, Quanli; Li, Jie; Yan, Huan; Lv, Yao; Shi, Huaiyin; Liu, Rong; Dai, Guanghai
肿瘤
肿瘤免疫
发表日期：2017
文献求助 收藏